Advanced Filters
noise

Neoplasms Clinical Trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,299 clinical trials

[18F]FES PET/.CT in Uterine Cancer

Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. [18F]fluoroestradiol (FES) PET/CT imaging …

18 years of age Female Phase 2
P Pascale Juneau, MASc

Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)

Upper tract urothelial cancer (UTUC) is cancer in the lining of the kidney or ureter (the tube that drains the kidney). This type of cancer is rare and as a result, there are only a few studies that have looked at it. Standard of care for UTUC would be surgery …

18 years of age All Phase 3
K Kai-Keen Shiu, PHD

NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer

Colorectal cancer (CRC) is the 2nd to 3rd most common malignant disease in developed countries, with over 1 million new cases and 500,000 deaths worldwide each year. The primary treatment for early stage CRC is surgery to remove the tumour, which is possible in 80% of patients. Even after surgery …

18 years of age All Phase 2
M Myong Cheol Lim

HIPEC for Platinum-Resistant Recurrent Ovarian Cancer

Platinum-resistant recurrent epithelial ovarian cancer randomizing with or without hyperthermic intraperitoneal chemotherapy (HIPEC)

18 years of age Female Phase 3
W Won Park

Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer

To investigate the non-inferiority of disease-free survival in women who received hypofractionated intensity-modulated whole pelvic radiation therapy (2.5 Gy x 16 fractions) after curative surgery for stage III endometrial cancer.

20 - 80 years of age Female Phase N/A
B Barbro Kristina Linderholm, P.I.

Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer

TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.

18 years of age All Phase N/A
N Nicole Culos-Reed, PhD

Yoga for Young Adults Affected by Cancer

Yoga may enhance physical and psychological outcomes among young adults affected by cancer. Yet, yoga has rarely been studied in this population. We developed and piloted a yoga program, which is now ready for implementation and evaluation. This single-group, mixed-methods project will explore effectiveness and implementation of the yoga program.

18 years of age All Phase N/A
Y Yunhong Tian, Doctor

Reduced Port Laparoscopic Gastrectomy for Gastric Cancer

Reduced port laparoscopic gastrectomy has been adopted in clinical. The safety and outcome of reduced port laparoscopic gastrectomy has not been systematically evaluated. The investigators sought to compare the short and long-term outcome of patients with gastric cancer who underwent reduced port gastrectomy with patients underwent traditional laparoscopic gastrectomy

18 - 90 years of age All Phase N/A
E Elise ROBERT

Chemoradiotherapy in Elderly Patients With Oesophagus Cancer

Management of elderly patient with cancer is a therapeutic challenge and a public health problem. The mean age of esophageal cancer is 64.5 years and 72.1 years in men and women respectively. Surgery is a standard treatment reserved to about 30 % of patients. The other 70 % are considered …

75 - 100 years of age All Phase 1/2
Y Yin U Liu, M.D

Reverse Triple Negative Immune Resistant Breast Cancer

This is a Phase II, open-label, three-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, or efavirenz) with immune checkpoint inhibitor in mTNBC (triple negative breast cancer) patients who progressed during previous immune checkpoint inhibitors.

18 - 70 years of age Female Phase 2

Simplify language using AI